Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Drug Pricing Reform In Medicare And Medicaid: Upcoming Regulatory Actions

Two highly anticipated proposed rules in Medicare Part D are scheduled for near-term release.

Pricing Debate Medicare

Government Action/Industry Reaction: HHS Sees Success In Approach To Drug Pricing Solutions

US HHS officials Azar and O’Brien tell a National Academy of Medicine forum that an important element of the Trump Administration’s approach to lowering drug prices is eliciting voluntary change from market players.

Pricing Debate Advertising, Marketing & Sales

Step Therapy For Anti-Inflammatories, ESAs Coming To UnitedHealthcare Medicare Plans

Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.

Pricing Debate Medicare

CVS Offering Point-Of-Sale Rebates In Part D Next Year With SilverScript Plan

Premiums will average about $80 for enhanced plan, well above average $32.50 premium for basic stand-alone Medicare Part D coverage in 2019.

Pricing Debate Medicare

GSK Returns To Paid External Experts For Physician Communications

Policy update reverses approach announced in 2013 on the basis that physicians prefer peer-to-peer communications with global expert practitioners, firm explains.

Advertising, Marketing & Sales Policy

Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics

Legislation headed to President Trump would also ban pharmacy "gag" clauses.

Biosimilars Pricing Debate
See All
Advertisement
UsernamePublicRestriction

Register